WebDisclosure WebDisclosure
Basculer en Français
11086 Companies
243495 Keywords
171660 Articles
131150 Press releases
Headlines Articles Press releases Utility Therapeutics Ltd. Remove
  1. Home
  2. Companies
  3. Utility Therapeutics Ltd.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 01/17/2024 at 12:00, 2 years 8 months ago

    UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

    UTILITY therapeutics Ltd. announces a private financing led by the AMR Action Fund and the U.S. FDA's acceptance of its New Drug Application (NDA) for PIVYA, a European-approved antibiotic for the treatment of uncomplicated urinary tract infections (UTIs). PIVYA has received the FDA's qualified infectious disease product (QIDP) designation, providing an additional 5 years of market exclusivity upon approval. This new antibiotic offers a unique mechanism of action and aims to address the rising rates of antimicrobial resistance. For more information, visit www.utilitytherapeutics.com.
    UTILITY Therapeutics PIVYA Urinary Tract Infections Antibiotic FDA Approval
    Logo of Utility Therapeutics Ltd.
Accesswire
  • Published on 09/28/2026 at 15:00, 3 hours 13 minutes ago

    Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia

  • Published on 09/28/2026 at 14:45, 3 hours 28 minutes ago

    Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

  • Published on 09/28/2026 at 14:30, 3 hours 43 minutes ago

    Drilling at Cat Creek Intersects a Copper-Molybdenum Porphyry System Visible Molybdenite-Chalcopyrite Over Significant Core Widths

  • Published on 09/28/2026 at 14:30, 3 hours 43 minutes ago

    Predictiv AI Completes United Nations Fleet Management Deployment Following Competitive Procurement Win

  • Published on 09/28/2026 at 14:00, 4 hours 13 minutes ago

    DoJ and DoW move to Support Resumption of Operations at Colosseum

View all ACCESSWIRE
EQS Group
  • Published on 09/28/2026 at 18:00, 13 minutes ago

    GEVELOT S.A.: Weekly declaration of share buybacks – 09/28/2026 (French only)

  • Published on 09/28/2026 at 18:00, 13 minutes ago

    GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 28/09/2026

  • Published on 09/28/2026 at 17:53, 20 minutes ago

    EQS-Adhoc: MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026

  • Published on 09/28/2026 at 17:49, 23 minutes ago

    XTPL increased its global project pipeline in H1 2026, building more sales opportunities for subsequent periods

  • Published on 09/28/2026 at 17:45, 27 minutes ago

    EQS-Adhoc: Airbus SE: Airbus reports share buyback transactions 21-25 September 2026

View all EQS
Les Echos
  • Published on 09/28/2026 at 17:54, 18 minutes ago

    Reporting on share buyback transactions carried out between September 21 and September 25, 2026

  • Published on 09/28/2026 at 17:54, 18 minutes ago

    Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026

  • Published on 09/28/2026 at 17:45, 28 minutes ago

    Weekly share buyback

  • Published on 09/28/2026 at 17:45, 28 minutes ago

    Déclaration hebdomadaire de rachat d'actions

  • Published on 09/28/2026 at 17:35, 38 minutes ago

    Déclaration hebdomadaire d'opérations effectuées du 21 au 25 septembre 2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy